Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving the request. Pancreatic cancer is among the most lethal cancers in existence, with a five-year survival rate of only about 3 percent for the most common metastatic form, and until now new treatment options have been frustratingly scarce for patients who have already tried conventional therapies. The speed of the FDA’s response was itself notable: the regulator received Revolution Medicines’ expanded access application on April 28th and signed it on April 30th, and the FDA Commissioner said the two-day turnaround reflects the agency’s commitment to getting promising treatments to patients with life-threatening conditions without delay. The pill works by targeting a protein called RAS, which is mutated in the majority of pancreatic cancer tumors and had for decades been considered essentially undruggable.

In a closely watched phase 3 trial called RASolute 302, daraxonrasib produced results the oncology community called unprecedented: patients taking the pill survived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death. The drug is taken orally once a day and was generally well tolerated in the trial, with no new safety signals reported. Daraxonrasib has also received Breakthrough Therapy and Orphan Drug designations from the FDA, and the company says it intends to submit a full new drug application under the FDA’s national priority program. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access to the drug for eligible patients across the United States.

Source: https://www.reuters.com/legal/litigation/us-fda-authorizes-early-access-revolutions-pancreatic-cancer-pill-2026-05-01/

PrevPreviousCommunities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78
NextA Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New HomeNext

Recent Articles

Happy News

Communities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78

May 10, 2026

According to the U.S. Data Center Moratorium Tracker, communities across the country have been pushing back against the rapid expansion of AI data centers with growing success, with the number of active bans and moratoriums jumping from just 8 in May 2025 to 78 today, including 50 active restrictions and

Read More
Happy News

An Alaska Animal Shelter Lets You Borrow A Dog For 48 Hours And It Is Leading To More Adoptions

May 10, 2026

The Anchorage Animal Care and Control shelter in Alaska launched a program in spring 2025 called Tails on Trails that has since become one of the most talked-about shelter initiatives in the country, pairing volunteers with a shelter dog for 48 hours and sending them out to explore the trails

Read More
Happy News

Scientists Gave Monkeys A Reward-Free Video Game And They Played Nearly 100 Rounds Anyway

May 10, 2026

Researchers at Kyoto University’s Institute for the Evolutionary Origins of Human Behavior set out to test whether curiosity in Japanese macaques follows the same pattern observed in humans, and what they found should resonate with anyone who has ever gone down a late-night internet rabbit hole for no practical reason

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.